Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

OBJECTIVE: THALES demonstrated that ticagrelor plus aspirin reduced the risk of stroke or death but increased bleeding versus aspirin during the 30 days following a mild-to-moderate acute non-cardioembolic ischaemic stroke (AIS) or high-risk transient ischaemic attack (TIA). There are no cost-effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Tank, Amarjeet, Johnston, S Claiborne, Jain, Ritika, Amarenco, Pierre, Mellström, Carl, Rikner, Klas, Denison, Hans, Ladenvall, Per, Knutsson, Mikael, Himmelmann, Anders, Evans, Scott R, James, Stefan, Molina, Carlos A, Wang, Yongjun, Ouwens, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450137/
https://www.ncbi.nlm.nih.gov/pubmed/37637218
http://dx.doi.org/10.1136/bmjno-2023-000478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450137/
https://www.ncbi.nlm.nih.gov/pubmed/37637218
http://dx.doi.org/10.1136/bmjno-2023-000478

Ejemplares similares